- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00539344
A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a phase 1, multi-centre, sequential cohort, open-label, dose-escalation study of the safety, tolerability, and PK of ANG1005 in patients with recurrent or progressive malignant glioma. ANG1005 will be given by IV infusion once every 21 days (1 treatment cycle). Each patient will participate in only 1 dose group and will receive up to 6 cycles. Patients may receive additional cycles of ANG1005 if there is no evidence of tumor progression, there is recovery to ≤Grade 1 or baseline nonhematologic, ANG1005-related toxicity (except alopecia), the absolute neutrophil count is ≥1.5 x 109/L, and the platelet count is ≥100 x 109/L.
Initially, cohorts of 1 - 3 patients will be enrolled into each dose group. Dose escalation by dose doubling will be done for the first 3 dose groups followed by a modified Fibonacci dose escalation scheme with increases of 67%, 50%, 40% and 33% thereafter. If > 1 patient in a cohort experience an emergent ≥ Grade 2 drug-related toxicity during the first treatment cycle, then a minimum of 3 patients will be enrolled into that, and all subsequent cohort(s) and dose doubling will be stopped if applicable.
If > 1 patient in a cohort experience a dose limiting toxicity (DLT) during the first treatment cycle, defined as any of the following that are both treatment-emergent and at least possibly related to ANG1005: i) Any Grade 3 or 4 nonhematologic toxicity, ii) Febrile neutropenia, iii) Grade 4 neutropenia of ≥7 days duration, and/or iv) Any Grade 4 thrombocytopenia, then dose escalation will stop and prior doses will be explored as the maximum tolerated dose (MTD), that dose-level at which ≤1 of 6 patients in a cohort develop an emergent DLT).
Once the MTD is established, approximately 14 patients will be enrolled at that dose-level in order to further assess the safety and tolerability of ANG1005, the PK profile of ANG1005 at the MTD, and the preliminary anti-tumor activity of ANG1005 in patients with malignant glioma.
Approximately 8 additional patients who are scheduled for debulking surgery for recurrent disease may be enrolled into a separate sub-study to obtain preliminary information about whether or not ANG1005 crosses the blood-brain barrier into malignant glioma tumors. These patients will receive ANG1005 prior to surgery at the dose level established to be safe and tolerable at that time and may continue to receive additional cycles of ANG1005 following surgery, if appropriate.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Dana Farber Cancer Institute
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Henry Ford Health System
-
-
New York
-
New York, New York, United States, 10032
- Irving Comprehensive Cancer Center, Columbia University Medical Center
-
-
Texas
-
Houston, Texas, United States, 77030
- University Of Texas, MD Anderson Cancer Center
-
San Antonio, Texas, United States, 78229
- UT Health Science Center at the Cancer Therapy and Research Center (CTRC)
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- University of Virginia Health System
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent
- Histologically confirmed malignant glioma
- Radiologically confirmed progression of malignant glioma
- Patients must, in the opinion of the investigator, be ineligible for current standard of care treatment
- No evidence of acute intracranial/intratumoral hemorrhage
- Male and female patients
- Age ≥18 years
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- An expected survival of at least 3 months
- Measurable disease according to Macdonald response criteria
- Male and female subjects who are not surgically sterile or post-menopausal must agree to use reliable methods of birth control for the duration of the study and for 90 days after the last dose of study drug administration; male partners of female subjects should use condoms for the duration of the study, and for 90 days after the last dose of study drug administration
Exclusion Criteria:
- Chemotherapy, radiotherapy (except palliative radiation delivered to <20% of bone marrow), or investigational agents within 4 weeks before the first dose of study drug. Biologic therapy (such as 13-cis-retinoic acid, thalidomide, tamoxifen, celebrex, erlotinib, imatinib, vorinostat, and lapatinib) and immunotherapy (such as interferon a or b, cdx-110 (EGFR vIII vaccine), interleukin 2, thalidomide) within 1 week before the first dose of study drug. Bevacizumab within 6 weeks before the first dose of study drug
- Pregnant or lactating females
- Any acute viral, bacterial, or fungal infection that requires parenteral therapy within 14 days prior to study treatment
- Known severe hypersensitivity to paclitaxel
- Severe toxicity with previous taxane treatment
- Patients being treated with P450 CYP 3A4 or CYP 2C8 enzyme-inducing anti-convulsant drugs within 14 days prior to treatment with study drug
- Patients with inadequate hematological, liver, and renal function
- Known or suspected acute or chronic active Hepatitis B, or Hepatitis C or HIV/AIDS
- Patients with unstable or uncompensated respiratory, cardiac, hepatic or renal disease or any other organ system dysfunction, medical condition, or laboratory abnormality which, in the opinion of the investigator, would either comprise the patient's safety or interfere with the evaluation of the test material
- Evidence of persistent Grade 2 or greater neurotoxicity
Study Plan
How is the study designed?
Design Details
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
|
IV infusion once every 21 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To characterize the safety and tolerability of intravenously administered ANG1005 in patients with malignant glioma.
Time Frame: On-going
|
On-going
|
To identify the maximum tolerated dose (MTD) of ANG1005 in patients with malignant glioma.
Time Frame: End of dose escalation
|
End of dose escalation
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To examine the pharmacokinetics (PK) of ANG1005.
Time Frame: End of study
|
End of study
|
To confirm the safety and tolerability of ANG1005 at the MTD.
Time Frame: End of dose escalation
|
End of dose escalation
|
To assess the immunogenicity of ANG1005.
Time Frame: End of study
|
End of study
|
To obtain preliminary information about the antitumor activity of ANG1005 in patients with malignant glioma.
Time Frame: On-going
|
On-going
|
To obtain preliminary information about whether or not ANG1005 crosses the blood- brain barrier into malignant glioma tumors (Sub-study).
Time Frame: On-going
|
On-going
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ANG1005-CLN-01
- FDA (HHSF223201310224C)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent or Progressive Malignant Glioma
-
City of Hope Medical CenterNational Cancer Institute (NCI); Food and Drug Administration (FDA)Active, not recruitingRecurrent Glioblastoma | Recurrent Malignant Glioma | Refractory Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma | Refractory Glioblastoma | Refractory WHO Grade II Glioma | Refractory WHO Grade III GliomaUnited States
-
Sabine Mueller, MD, PhDPacific Pediatric Neuro-Oncology ConsortiumRecruitingGlioblastoma | Malignant Glioma | Recurrent Glioblastoma | Recurrent Malignant Glioma | Recurrent Grade III Glioma | Grade III GliomaUnited States, Australia, Israel, Switzerland
-
Jonsson Comprehensive Cancer CenterUnited States Department of DefenseRecruitingGlioma | Malignant Glioma | Recurrent Malignant Glioma | Recurrent GliomaUnited States
-
Oblato, Inc.Active, not recruitingRecurrent Malignant GliomaUnited States
-
INSYS Therapeutics IncPediatric Brain Tumor Consortium (PBTC), St. Jude Children's Research HospitalWithdrawnRecurrent Malignant GliomaUnited States
-
Memorial Sloan Kettering Cancer CenterM.D. Anderson Cancer Center; University of California, Los Angeles; University... and other collaboratorsActive, not recruitingGlioma | Recurrent Malignant GliomaUnited States
-
Medical University InnsbruckRoche, AustriaUnknownRecurrent Malignant GliomaAustria
-
National Cancer Institute (NCI)Active, not recruitingGlioblastoma | WHO Grade 3 Glioma | Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Glioma | Recurrent Cholangiocarcinoma | WHO Grade 2 GliomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingRecurrent Glioblastoma | Recurrent Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II GliomaUnited States
-
Oblato, Inc.Active, not recruitingRecurrent Malignant Glioma | Brain GlioblastomaUnited States
Clinical Trials on ANG1005
-
Angiochem IncNo longer availableAnaplastic Astrocytoma | Anaplastic Oligodendroglioma | Leptomeningeal Carcinomatosis | Breast Cancer With Recurrent Brain MetastasesUnited States
-
Angiochem IncCompletedAdvanced Solid Tumors With and Without Brain MetastasesUnited States
-
Angiochem IncTerminatedNon-small Cell Lung Cancer (NSCLC) With Brain MetastasesUnited States, Canada
-
Angiochem IncCompletedBreast Cancer | Brain MetastasesUnited States
-
Angiochem IncCompletedBreast Cancer | Brain MetastasesUnited States
-
Angiochem IncCompletedGlioma | Glioblastoma | Brain Tumor, RecurrentUnited States
-
Angiochem IncNot yet recruitingBrain Metastases | Leptomeningeal Metastases | HER2-negative Breast Cancer | Leptomeningeal Carcinomatosis